KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Assets Average (2020 - 2025)

Royalty Pharma's Assets Average history spans 6 years, with the latest figure at $19.5 billion for Q4 2025.

  • For Q4 2025, Assets Average rose 7.45% year-over-year to $19.5 billion; the TTM value through Dec 2025 reached $19.5 billion, up 7.45%, while the annual FY2025 figure was $18.9 billion, 9.36% up from the prior year.
  • Assets Average for Q4 2025 was $19.5 billion at Royalty Pharma, up from $18.8 billion in the prior quarter.
  • Across five years, Assets Average topped out at $19.5 billion in Q4 2025 and bottomed at $16.0 billion in Q1 2021.
  • The 5-year median for Assets Average is $17.3 billion (2022), against an average of $17.3 billion.
  • The largest annual shift saw Assets Average fell 6.88% in 2023 before it increased 12.49% in 2024.
  • A 5-year view of Assets Average shows it stood at $17.6 billion in 2021, then dropped by 2.16% to $17.2 billion in 2022, then decreased by 6.52% to $16.1 billion in 2023, then increased by 12.49% to $18.1 billion in 2024, then increased by 7.45% to $19.5 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Assets Average are $19.5 billion (Q4 2025), $18.8 billion (Q3 2025), and $18.0 billion (Q2 2025).